MondayNightIBD | Adalimumab Biosimilars Coming in 2023 | November 28, 2022 - Shubha Bhat, PharmD, MS, BCACP Post-test

In order to receive credit for this activity, you must read the front matter, view the activity, complete the post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

Question Title

1. Where are you in your career? (Required.)

IBD Specialist

General GI

Trainee/Fellow

APP

PharmD

Other (please specify)

Question Title

2. A 39 year-old female with pancolitis #UC currently on adalimumab 40 mg SQ Q2 weeks and in remission. Receives letter from insurance re: need to switch to adalimumab biosimilar and contacts GI office.

How do you proceed?

Switch to adalimumab biosimilar

Appeal switch to keep on reference adalimumab

Switch to alternative medication

Question Title

3. Which adalimumab biosimilar has interchangeability status?

Abrilada

Cyltezo

Amjevita

Hulio

EVALUATION FORM

Question Title

4. Upon completion of this activity, I am able to:

	Strongly agree	Agree	Disagree	Strongly disagree
IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Strongly agree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Agree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Disagree	IDENTIFY guideline-directed strategies and best practices for the care of patients with IBD Strongly disagree
RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management	RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Strongly agree	RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Agree	RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Disagree	RECOGNIZE safety and efficacy data from clinical trials of new and emerging agents to achieve an individualized, patient-centered approach to IBD management Strongly disagree
ANALYZE potential approaches for positioning new and emerging therapies for UC	ANALYZE potential approaches for positioning new and emerging therapies for UC Strongly agree	ANALYZE potential approaches for positioning new and emerging therapies for UC Agree	ANALYZE potential approaches for positioning new and emerging therapies for UC Disagree	ANALYZE potential approaches for positioning new and emerging therapies for UC Strongly disagree
EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Strongly agree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Agree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Disagree	EVALUATE complex clinical situations in which patients with IBD may benefit from management strategies including novel therapeutics Strongly disagree

Question Title

5. Please indicate the extent of your agreement with the following statements:

	Strongly agree	Agree	Disagree	Strongly disagree
The faculty for this activity were effective	The faculty for this activity were effective Strongly agree	The faculty for this activity were effective Agree	The faculty for this activity were effective Disagree	The faculty for this activity were effective Strongly disagree
The educational resources and/or handouts provided to me at the educational activity are useful to my practice	The educational resources and/or handouts provided to me at the educational activity are useful to my practice Strongly agree	The educational resources and/or handouts provided to me at the educational activity are useful to my practice Agree	The educational resources and/or handouts provided to me at the educational activity are useful to my practice Disagree	The educational resources and/or handouts provided to me at the educational activity are useful to my practice Strongly disagree

Question Title

6. Overall, was this activity fair, balanced and free from commercial bias?

Yes

Question Title

7. If no, please explain:

Question Title

8. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

9. I will make the following changes to my practice based on what I learned today (check all that apply):

Greater understanding of biosimilars expected to launch in 2023

Knowledge of differences and similarities of biosimilar treatment options

Best practices of my colleagues and leaders

I do not plan on making changes to my practice at this time

Other (explain)

Question Title

10. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding evidence-based strategies

Lack of convincing evidence to warrant change

Lack of time/resources to consider change

Insurance, reimbursement or legal issues

Patient adherence/resistance to change

Other (please specify)

Question Title

11. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information. (Required.)

First Name *

Last Name *

Degree/Credentials:

City

State/Province

ZIP/Postal Code *

Country

Email Address (required to receive credit) *

Question Title

12. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Adalimumab Biosimilars Coming in 2023" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)

Yes

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

MondayNightIBD | Adalimumab Biosimilars Coming in 2023 | November 28, 2022 - Shubha Bhat, PharmD, MS, BCACP *Post-test*

Question Title

* 1. Where are you in your career? (Required.)

Question Title

* 2. A 39 year-old female with pancolitis #UC currently on adalimumab 40 mg SQ Q2 weeks and in remission. Receives letter from insurance re: need to switch to adalimumab biosimilar and contacts GI office.How do you proceed?

Question Title

* 3. Which adalimumab biosimilar has interchangeability status?

Question Title

* 4. Upon completion of this activity, I am able to:

Question Title

* 5. Please indicate the extent of your agreement with the following statements:

Question Title

* 6. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 7. If no, please explain:

Question Title

* 8. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 9. I will make the following changes to my practice based on what I learned today (check all that apply):

Question Title

* 10. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 11. For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.* (Required.)

Question Title

* 12. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Adalimumab Biosimilars Coming in 2023" and claim 1.0 AMA PRA Category 1 CreditTM. (Required.)

MondayNightIBD | Adalimumab Biosimilars Coming in 2023 | November 28, 2022 - Shubha Bhat, PharmD, MS, BCACP Post-test

1. Where are you in your career? (Required.)

2. A 39 year-old female with pancolitis #UC currently on adalimumab 40 mg SQ Q2 weeks and in remission. Receives letter from insurance re: need to switch to adalimumab biosimilar and contacts GI office.

How do you proceed?

3. Which adalimumab biosimilar has interchangeability status?

4. Upon completion of this activity, I am able to:

5. Please indicate the extent of your agreement with the following statements:

6. Overall, was this activity fair, balanced and free from commercial bias?

7. If no, please explain:

8. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

9. I will make the following changes to my practice based on what I learned today (check all that apply):

10. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

11. For purposes of certification, please complete the following information. Please note that we will not forward or sell your contact information. (Required.)

12. I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Adalimumab Biosimilars Coming in 2023" and claim 1.0 AMA PRA Category 1 Credit^TM. (Required.)